HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
THURSDAY, March 28, 2019 (HealthDay News) -- The drug artesunate -- the World Health Organization-recommended first-line treatment for severe malaria -- will become the first-line treatment for severe malaria in the United States, the U.S. Centers for Disease Control and Prevention says in a new guidance to health care providers.
The new guidance marks a change in U.S. treatment protocol that became necessary after the only U.S. Food and Drug Administration-approved intravenous (IV) antimalarial drug in the United States -- quinidine -- was discontinued by the maker.
Currently, artesunate is not FDA approved or commercially available in the United States, so the CDC will use a special FDA regulatory measure to ensure that IV artesunate is available for the treatment of severe malaria.
Starting April 1, health care providers must call the CDC Malaria Hotline (1-770-488-7788) to obtain the IV artesunate. After a CDC expert confirms that IV artesunate is needed, the drug will be released free of charge to the CDC quarantine station closest to the requesting hospital, and a hospital representative can pick up the drug at the station. The CDC is stocking artesunate at 10 quarantine stations and will work with the stations and hospitals to ensure swift delivery of the drug. There will be a sufficient supply of IV artesunate for treatment of all cases of severe malaria in the United States, according to the CDC.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on May 27, 2022